Table 1.
Baseline patient characteristics based on the type of graft
| Characteristic | Fresh | Cryopreserved |
|---|---|---|
| No. of patients | 2499 | 1543 |
| Age at transplantation (y), n (%) | ||
| Median (min-max) | 55 (0-79) | 58 (0-82) |
| 0-9 | 209 (8) | 61 (4) |
| 10-17 | 159 (6) | 57 (4) |
| 18-29 | 249 (10) | 116 (8) |
| 30-39 | 182 (7) | 143 (9) |
| 40-49 | 266 (11) | 185 (12) |
| 50-59 | 436 (17) | 290 (19) |
| 60-69 | 746 (30) | 503 (33) |
| 70+ | 252 (10) | 188 (12) |
| Race, n (%) | ||
| White | 2016 (81) | 1317 (85) |
| Black or African American | 201 (8) | 91 (6) |
| Asian | 109 (4) | 45 (3) |
| Native Hawaiian or other Pacific Islander | 6 (0) | 3 (0) |
| American Indian or Alaska Native | 10 (0) | 7 (0) |
| More than 1 race | 22 (1) | 5 (0) |
| Missing | 135 (5) | 75 (5) |
| Ethnicity, n(%) | ||
| Hispanic or Latino | 311 (12) | 164 (11) |
| Not Hispanic or Latino | 2100 (84) | 1298 (84) |
| Missing∗ | 88 (4) | 81 (5) |
| HCT-CI, n (%) | ||
| 0-2 | 1272 (51) | 842 (55) |
| 3+ | 1206 (48) | 688 (45) |
| Missing | 21 (1) | 13 (1) |
| Karnofsky/Lansky performance score, n (%) | ||
| 0-80 | 1011 (40) | 660 (43) |
| 90-100 | 1429 (57) | 850 (55) |
| Missing | 59 (2) | 33 (2) |
| Disease, n (%) | ||
| AML | 921 (37) | 588 (38) |
| ALL | 338 (14) | 251 (16) |
| MDS | 480 (19) | 301 (20) |
| Lymphoma | 163 (7) | 121 (8) |
| Other leukemias | 128 (5) | 77 (5) |
| Other malignancies | 180 (7) | 111 (7) |
| SAA | 104 (4) | 40 (3) |
| Nonmalignant diseases | 185 (7) | 54 (3) |
| Disease status, n (%) | ||
| CR1/2 or early MDS | 1184 (47) | 787 (51) |
| Other disease status, other malignancy, or nonmalignant disease | 1315 (53) | 756 (49) |
| DRI | ||
| Low | 133 (5) | 68 (4) |
| Intermediate | 1113 (44) | 790 (51) |
| High | 447 (18) | 259 (17) |
| Very high | 51 (2) | 30 (2) |
| Missing | 118 (5) | 121 (8) |
| Nonmalignant disease | 289 (12) | 94 (6) |
| Not applicable | 384 (14) | 181 (12) |
| Conditioning intensity, n (%) | ||
| MAC | 1031 (41) | 645 (42) |
| RIC | 924 (37) | 593 (38) |
| NMA | 248 (10) | 209 (14) |
| Missing | 7 (0) | 2 (0) |
| N/A, not malignant disease | 289 (12) | 94 (6) |
| Conditioning intensity, n (%) | ||
| MAC | 1031 (41) | 645 (42) |
| RIC/NMA | 1172 (47) | 802 (52) |
| Nonmalignant, no drugs, or missing | 296 (12) | 96 (6) |
| GVHD Prophylaxis, n (%) | ||
| Ex vivo T-cell depletion | 38 (2) | 9 (1) |
| CD34 selection | 27 (1) | 0 (0) |
| Post-Cy | 767 (31) | 579 (38) |
| Tac based | 1448 (58) | 859 (56) |
| CsA based | 175 (7) | 56 (4) |
| Other | 18 (1) | 20 (1) |
| Missing | 26 (1) | 20 (1) |
| ATG/alemtuzumab use, n (%) | ||
| No | 1778 (71) | 1155 (75) |
| Yes | 721 (29) | 388 (25) |
| Donor, n (%) | ||
| HLA-identical sibling | 378 (15) | 150 (10) |
| Other related | 467 (19) | 200 (13) |
| Well-matched unrelated (8/8) | 1449 (58) | 1037 (67) |
| Mismatched unrelated | 205 (8) | 150 (10) |
| Missing | 0 (0) | 6 (0) |
| Donor center location, n (%) | ||
| Domestic | 703 (28) | 588 (38) |
| International | 956 (38) | 639 (41) |
| No donor center, related donor | 839 (34) | 314 (20) |
| Missing | 1 (0) | 2 (0) |
| No. of PBSC collection days | ||
| One-day collection | 1023 (41) | 886 (57) |
| Two-day collection | 218 (9) | 184 (12) |
| N/A, BM | 665 (26) | 182 (12) |
| Missing, related donor | 593 (24) | 291 (19) |
| Donor/recipient sex match, n (%) | ||
| M-M | 1013 (41) | 547 (35) |
| M-F | 589 (24) | 392 (25) |
| F-M | 463 (19) | 294 (19) |
| F-F | 417 (17) | 286 (19) |
| Missing | 17 (1) | 24 (2) |
| Donor/recipient CMV serostatus, n (%) | ||
| +/+ | 816 (33) | 473 (31) |
| +/− | 303 (12) | 186 (12) |
| −/+ | 676 (27) | 492 (32) |
| −/− | 686 (27) | 380 (25) |
| Missing | 18 (1) | 12 (1) |
| Graft type, n (%) | ||
| BM | 665 (27) | 182 (12) |
| Peripheral blood | 1834 (73) | 1361 (88) |
| CD34 for PB, or TNC for BM above or below median, n (%) | ||
| ≤median | 1244 (50) | 972 (63) |
| >median | 1255 (50) | 571 (37) |
| TNC (×108/kg) for BM | ||
| n | 584 | 131 |
| Median (min-max) | 3.1 (0.01-767.5) | 2.5 (0.04-13.1) |
| 5th-95th pctl | 0.9-8.5 | 0.9-6.7 |
| CD34(×106/kg) for peripheral blood | ||
| n | 1810 | 1199 |
| Median (min-max) | 6.3 (0.02-83855.4) | 5.7 (0.01-3478.4) |
| 5th-95th pctl | 2.6-16.1 | 2.5-12.9 |
| Y of transplant, n (%) | ||
| 2019 | 2499 (100) | 0 (0) |
| 2020 | 0 (0) | 1543 (100) |
| Follow-up (d) - median (range) | 373 (27-524) | 372 (22-540) |
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; ATG, anti-thymocyte globulin; CMV, cytomegalovirus; CsA, cyclosporine A; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; NMA, non-myeloablative; pctl, percentile; RIC, reduced intensity conditioning; SAA, severe aplastic anemia; TNC, total nucleated cell count.
∗
Includes NA, nonresident of the United States: n = 24 in the group with fresh grafts, and n = 8 in the group with cryopreserved grafts.